Søsterhjemmet, Kirkeveien 166, 2.etasje (map)
Jodie Goodridge and Karl-Johan Malmberg have received a grant from The Research Council of Norway (RCN) Toppforsk for the project "Programming natural killer cell function through the organelle communication". Their application was among the 16% that was granted.
Senterleder Johanna Olweus i intervju med Aftenposten Vitenskap om sitt arbeid innenfor immunterapi.
Karl-Johan Malmberg has received funding from The Norwegian Cancer Society of 8,95 mill. NOK.
The research group of Johanna Olweus, together with Kite Pharma, will further develop breakthrough technology on immunotherapy against cancer.
In connection with American Society of Clinical Oncology (ASCO) naming immunotherapy as the Society’s advance of the year, Professor Johanna Olweus and Professor Karl-Johan Malmberg was interviewed by Dagens Medisin, April 12th 2017.
Malmberg Lab enter into partnership with Fate Therapeutics Inc. to develop off-the-shelf NK cell therapy
The conference explores possibilities for how to create a leading Nordic Life Science hub for research, education, innovation and business focusing this year on health.
Professor and co-Director of K.G. Jebsen Centre of Immunotherapy Karl-Johan Malmberg speaks on "Harnessing Natural Killer Cells in Cancer Immunotherapy" during STREAM mini-symposium.
JCIT Director Professor Johanna Olweus was invited to present immunotherapy, current strategies and comment on K.G. Jebsen Centre’s current work.
Oslo University Hospital gives prizes to six outstanding research articles with key authors from the hospital every six months.
Every year The Norwegian Cancer Society supports cancer Research. In 2016 a total of 40 million NOK was granted to immunotherapy.
Researchers from the KG Jebsen Centres for Cancer Immunotherapy (JCIT) and Inflammation Research (JIRC) collaborate to develop tomorrow's tools for protein analysis.
Karl-Johan Malmberg, PI in the Jebsen Center for cancer Immunotherapy has been appointed as visiting professor at the Karolinska Institute (KI).
Poorly validated antibodies represent one of the largest problems in bio-medical research.